What The Study Did: Researchers evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic (blood) cancers and COVID-19.
Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai scientists in Nature in June.
Scientists have identified how and why some Covid-19 patients can develop life-threatening clots, which could lead to targeted therapies that prevent this from happening.
State-of-the-art video microscopy has enabled Australian researchers to see the molecular details of how malaria parasites invade red blood cells - a key step in the disease.
Sickle cell disease leads to chronic pain, organ failure, and early death in patients worldwide. A team led by Broad Institute of MIT and Harvard and St. Jude Children's Research Hospital has demonstrated a gene editing approach that efficiently corrects the mutation underlying SCD in patient blood stem cells and in mice. This treatment rescued disease symptoms in animal models, enabling long-lasting production of healthy blood cells, and could inspire a therapeutic strategy for SCD.
Story tips from Johns Hopkins experts on COVID-19
Researchers from the University of Pittsburgh used a whole-body 7-Tesla MRI scanner alongside their optimized Tic-Tac-Toe RF head coil system to study sickle cell disease's impact on the brain. They discovered that SCD can have a severe effect on specific subfields of the hippocampus - a highly complex part of the human brain that controls learning and memory and is very susceptible to injury or disorders.
Imperial researchers have designed drug delivery nanocapsules that could reduce the side effects of a major blood clot dissolving drug.
A new miniature 3D model of human bone marrow has been described today in the open-access eLife journal. The model may help clinicians predict which patients will benefit from a new therapy for blood platelet disorders, such as Inherited Thrombocytopenias -- a group of familial disorders that inhibit the production of platelets. It could also enable further study of these disorders and give scientists a new tool to test experimental treatments.
Researchers at Children's Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin. Using a viral vector engineered to reactivate fetal hemoglobin production, suppress mutant hemoglobin, and supply functional adult hemoglobin, the researchers developed an approach that could produce more hemoglobin through a single vector. The results were published in Haematologica.